source
- GSK pursues China-centric growth after successful Hansoh licensing deals show promiseGSK says it is following a "balance West and East" strategy, increasingly looking to China for drug licensing opportunities. In 2023 the company paid a combined $270 million upfront to Hansoh Phar…
- Celldex reports dual Phase 3 successes for barzolvolimab in refractory chronic spontaneous urticariaCelldex Therapeutics announced that its monoclonal antibody barzolvolimab achieved positive results in two Phase 3 studies of patients with treatment-refractory chronic spontaneous urticaria. The E…